-SEC Filing
Needham Maintains Buy on Blueprint Medicines, Lowers Price Target to $57
Needham analyst Ami Fadia maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and lowers the price target from $60 to $57.
Related Posts
Siyata Mobile Earns Follow-On Order From Major Cellular Client
Siyata Mobile (NASDAQ:SYTA) stock is on a bullish run, with shares higher by over 73% YTD following a near 11% spike on Wednesday. To those following SYTA, the move is not surprising. In fact, many
Tesla On The Cusp Of Massive 20% Job Cuts Amid Fundamental Woes, Stock Slump: Report
Ahead of what is widely expected to be a dismal quarter, Tesla is rumored to be eyeing job cuts amid a tough environment.
J.Jill’s Ability For Ongoing Topline Gains & Increased Profitability Impresses This Analyst
Telsey Advisory Group analyst Dana Telsey reiterated a Moderate Risk rating on the shares of J.Jill Inc (NYSE:JILL) and raised the price…